- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about NVO
Recent news which mentions NVO
Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
December 20, 2024
From Benzinga
Elon Musk Vs. RFK Jr.: Obesity Crisis Debate Sparks Struggle For Trump's Influence
December 19, 2024
From Benzinga
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
December 19, 2024
From Benzinga
Got $250? 2 Healthcare Stocks to Buy and Hold Forever
December 19, 2024
From Motley Fool
21% of Warren Buffett's "Secret" Portfolio Is Invested in These 3 ETFs. Are They Great Picks for 2025?
December 19, 2024
From Motley Fool
This Is Huge News for Eli Lilly Investors
December 19, 2024
From Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
December 18, 2024
From Benzinga
Novo Nordisk's Ozempic Under Scrutiny For Potential Increased Risk Of Rare-Eye Disease
December 18, 2024
From Benzinga
Ozempic Dethroned? A Head-to-Head Study Confirms This Company Has the Best Weight Loss Drug
December 18, 2024
From Motley Fool
5 Top European Stocks to Buy Before 2025
December 16, 2024
From Motley Fool
Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent
December 16, 2024
From Benzinga
Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?
December 15, 2024
From Motley Fool
Novo Nordisk's Ozempic Potentially Linked To Rare Vision Loss Risk, But Absolute Risk Is Low: Study
December 13, 2024
From Benzinga
3 Growth Stocks That Can Be No-Brainer Buys in 2025
December 13, 2024
From Motley Fool
Novo Nordisk's Ozempic Label Expansion Snags Approval From European Drug Regulator's Advisory Panel
December 12, 2024
From Benzinga
Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound
December 12, 2024
From Benzinga
2 No-Brainer Growth Stocks to Buy and Hold Through 2025 and Beyond
December 12, 2024
From Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
December 11, 2024
From Benzinga
From Benzinga
Warning: This Skyrocketing Stock Has a Hidden Risk
December 10, 2024
From Motley Fool
Eli Lilly Stock Just Got Even Sweeter. Here's Why It's Worth Buying Now
December 09, 2024
From Motley Fool
Deal Dispatch: Ubisoft In Buyout Talks, Dental Supplier Explores Sale, Beloved Drive-Through Goes Bankrupt
December 07, 2024
From Benzinga
3 No-Brainer Growth Stocks to Buy in December
December 07, 2024
From Motley Fool
Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.
December 07, 2024
From Motley Fool
How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals
December 05, 2024
From Benzinga
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?
December 05, 2024
From Motley Fool
Wegovy Maker Novo Nordisk To Buy Novavax's Czech Republic Manufacturing Facility For $200 Million
December 04, 2024
From Benzinga
10 Health Care Stocks Whale Activity In Today's Session
December 04, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.